Kaplan-Meier probabilities of survival among patients with advanced CLL who were treated with allo-NMA-HCT as stratified into four risk groups on the basis of consolidated HCT-CI scores and lymph node diameter. Group I included patients who had no comorbidities and who had lymphadenopathy of < 5 cm (n = 28); group II, patients with comorbidities only (n = 34); group III, patients with lymphadenopathy of ≥ 5 cm only (n = 7); and group IV, patients with both comorbidities and lymphadenopathy of ≥ 5 cm (n = 13). Five-year survival rates were 78%, 60%, 43%, 27% for risk groups I, II, III, and IV, respectively. (From Sorror et al., 2008.⁴³  Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved.)